GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » Operating Margin %

ENDV (Endonovo Therapeutics) Operating Margin % : 0.00% (As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Endonovo Therapeutics's Operating Income for the three months ended in Mar. 2025 was $-0.23 Mil. Endonovo Therapeutics's Revenue for the three months ended in Mar. 2025 was $0.00 Mil. Therefore, Endonovo Therapeutics's Operating Margin % for the quarter that ended in Mar. 2025 was 0.00%.

Good Sign:

Endonovo Therapeutics Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Endonovo Therapeutics's Operating Margin % or its related term are showing as below:

ENDV' s Operating Margin % Range Over the Past 10 Years
Min: -64125   Med: -2734.23   Max: -1228.71
Current: -51550


ENDV's Operating Margin % is ranked worse than
97.15% of 983 companies
in the Biotechnology industry
Industry Median: -115.49 vs ENDV: -51550.00

Endonovo Therapeutics's 5-Year Average Operating Margin % Growth Rate was 5.00% per year.

Endonovo Therapeutics's Operating Income for the three months ended in Mar. 2025 was $-0.23 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.03 Mil.

Warning Sign:

Endonovo Therapeutics Inc has never been profitable in the past 3 years. It lost money every year.


Endonovo Therapeutics Operating Margin % Historical Data

The historical data trend for Endonovo Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics Operating Margin % Chart

Endonovo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,228.71 -1,754.22 -3,050.68 -2,417.78 -2,085.00

Endonovo Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13,100.00 -5,000.00 -20,600.00 - -

Competitive Comparison of Endonovo Therapeutics's Operating Margin %

For the Biotechnology subindustry, Endonovo Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endonovo Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Operating Margin % falls into.


;
;

Endonovo Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Endonovo Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-2.919 / 0.14
=-2,085.00 %

Endonovo Therapeutics's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2025 ) / Revenue (Q: Mar. 2025 )
=-0.231 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endonovo Therapeutics  (OTCPK:ENDV) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Endonovo Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Endonovo Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc is an USA-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Executives
Alan Brian Collier director, 10 percent owner, officer: CEO 6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann 10 percent owner, officer: President 6320 CANOGA AVENUE, WOODLAND HILLS CA 91367